Drug Safety
Prove that New Drugs Are Safe
Drug safety is a critical focus for pharmaceutical companies. However, it is easy to overlook safety signals because adverse biological effects often consist of subtle changes in multi-dimensional markers and measurement patterns. Relevance can be determined more quickly and easily by visually analyzing volumes of complex data from diverse sources in real time.
At Novartis, TIBCO analytics and visualization are key technologies used to graphically analyze interactive data for both preclinical and clinical studies, improving both detection and systematic assessment of safety signals. The team compares effects across different indications, understanding disease and population-specific differences in the safety profiles of a drug candidate.
With TIBCO visualization and analytics, decisions are made earlier in the project cycle as adverse events are spotted sooner. Project teams effectively monitor safety biomarkers over time and identify risk factors in subpopulations based on incidence information, normal target ranges, and high dimensional, high volume data. Researchers can search for multi-dimensional changes in safety biomarkers, test assumptions, generate and pre-test hypotheses, and define plots to display relevant safety findings. Results are normalized to be practical and understandable.
